Palovarotene: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 6, p. 711, doi. 10.1007/s40265-022-01709-z
- By:
- Publication type:
- Article
Works matching IS 00126667 AND DT 2022 AND VI 82 AND IP 6
Results: 10
1
2
Correction to: Interchangeability of Biosimilars: Overcoming the Final Hurdles.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
3
Clazosentan: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 6, p. 697, doi. 10.1007/s40265-022-01708-0
- By:
- Publication type:
- Article
4
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
- Published in:
- Drugs, 2022, v. 82, n. 6, p. 683, doi. 10.1007/s40265-022-01705-3
- By:
- Publication type:
- Article
5
Tebentafusp: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 6, p. 703, doi. 10.1007/s40265-022-01704-4
- By:
- Publication type:
- Article
6
Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals.
- Published in:
- Drugs, 2022, v. 82, n. 6, p. 633, doi. 10.1007/s40265-022-01701-7
- By:
- Publication type:
- Article
7
Gefapixant: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 6, p. 691, doi. 10.1007/s40265-022-01700-8
- By:
- Publication type:
- Article
8
Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer.
- Published in:
- Drugs, 2022, v. 82, n. 6, p. 649, doi. 10.1007/s40265-022-01698-z
- By:
- Publication type:
- Article
9
BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
- Published in:
- Drugs, 2022, v. 82, n. 6, p. 613, doi. 10.1007/s40265-022-01697-0
- By:
- Publication type:
- Article
10
Pharmacological Treatment for Pedophilic Disorder and Compulsive Sexual Behavior Disorder: A Review.
- Published in:
- Drugs, 2022, v. 82, n. 6, p. 663, doi. 10.1007/s40265-022-01696-1
- By:
- Publication type:
- Article